Last updated: February 19, 2026
What is the Scope of AU2010297357?
The patent AU2010297357, titled "Antibody combinations for treatment or prevention of cancer," covers monoclonal antibody combinations specifically designed to target PD-1 (programmed death-1) and PD-L1 (programmed death-ligand 1). The patent's scope extends to methods of using these combinations for treating various cancers, including melanoma, lung carcinoma, renal cell carcinoma, and other solid tumors.
The patent defines two primary elements: a first antibody targeting PD-1 and a second antibody targeting PD-L1. It encompasses variations where these antibodies are administered sequentially or concurrently, as well as formulations combining these antibodies within a single pharmaceutical composition.
The claims are broad enough to include both humanized and chimeric antibodies, with specific mention of monoclonal antibodies such as pembrolizumab and atezolizumab. The patent also covers methods of producing these antibody combinations and their use in combination therapies.
What Are the Key Claims?
Independent Claims
-
Claim 1: A method of treating cancer involving administering a combination comprising an anti-PD-1 antibody and an anti-PD-L1 antibody, either simultaneously or sequentially. It specifies the antibodies can be humanized, murine, or chimeric.
-
Claim 2: A pharmaceutical composition containing the same combination, formulated for systemic administration.
-
Claim 3: A use of the combination for preparing a medicament to treat cancers characterized as solid tumors, melanoma, non-small cell lung cancer, or renal cell carcinoma.
Dependent Claims
-
Claims specify the antibodies can be selected from known therapeutic agents like pembrolizumab (Keytruda), nivolumab, atezolizumab, and durvalumab.
-
Claims cover various dosages, routes of administration, and treatment regimens.
-
Claims encompass methods of producing the antibody combinations, including conjugation and formulation processes.
Scope Considerations
The claims’ phrasing covers:
-
Both individual antibodies and their combinations.
-
Multiple therapeutic indications involving different cancer types.
-
Variations in the timing (simultaneous or sequential) of antibody administration.
Subclaims narrow the scope to specific antibody variants and formulations but do not limit the patent to particular brands or molecules, allowing broad application within the antibody combination landscape.
Patent Landscape Overview
Priority and Family
-
Priority date: September 24, 2009 (filing in the United States, US provisional application).
-
Family members: The patent family extends to multiple jurisdictions, including the US, Europe, China, and Japan, indicating strategic global protection.
Competitor and Patent Activities
-
Key players: Merck (Keytruda/pembrolizumab), Roche (atezolizumab), Bristol-Myers Squibb (nivolumab), and AstraZeneca (durvalumab) hold foundational patents related to PD-1/PD-L1 inhibitors.
-
Patent filings: Numerous patents protect specific antibodies, methods of use, and combination therapies targeting PD-1/PD-L1.
-
Litigation and opposition: The landscape involves several patent disputes and opposition proceedings, notably concerning the use and combination claims.
Patent Validity and Challenges
-
Claims are supported by extensive biological data demonstrating efficacy in vitro and in vivo.
-
Validity could be challenged based on prior art, especially any earlier disclosures of antibody combinations or methods using anti-PD-1 and anti-PD-L1 simultaneously.
-
Patent term adjustments could extend expiry into the late 2020s or early 2030s, depending on maintenance payments and patent term extensions.
Trends and Opportunities
-
Increasing focus on combination immunotherapies aims to improve response rates and overcome resistance.
-
The scope of claims aligning to specific antibody pairs suggests potential for patent infringement suits if a competing antibody combination is developed.
-
Filing activity shows an emphasis on specific dosing regimens, formulations, and methods of delivery.
Strategic Considerations for Stakeholders
-
For generics and biosimilars: The broad scope covering multiple antibody variants and combinations could pose barriers to entry until patent expiry or licensing.
-
For innovator companies: The patent offers a robust barrier against competitors developing similar combination therapies.
-
For licensees: Licensing negotiations will require addressing the scope of claims and potential for patent challenge based on prior art.
Conclusion
The AU2010297357 patent secures broad rights to antibody combinations targeting PD-1 and PD-L1 for cancer treatment. Its claims cover various antibodies, formulations, and methods, making it a significant asset within the immuno-oncology IP landscape. The patent's strategic value depends on the continued validity of claims, potential for infringement, and the evolving landscape of immunotherapy patents.
Key Takeaways
-
The patent covers both the composition and methods of using PD-1/PD-L1 antibody combinations for oncology.
-
Claims are broad, including multiple antibodies, uses, and formulations.
-
The patent family has international protection, indicating an intent for global commercialization.
-
Competitors and biosimilar developers should scrutinize claim language and patent family members for potential infringement risks.
-
Patent expiry is likely around 2029-2030, subject to patent term adjustments and maintenance.
FAQs
1. Can this patent be licensed for development of new combination therapies?
Yes. Licensing depends on negotiations with patent holders and understanding claim scope.
2. Are the claims specific to certain antibodies?
Claims cover several antibodies, including pembrolizumab and atezolizumab, but are broad enough to include subclasses and variants.
3. Does the patent cover monotherapy or only combinations?
It primarily claims combination therapy but also includes methods of administering single antibodies.
4. What are the risks of patent invalidity?
Potential challenges include prior art that discloses similar antibody combinations or methods, especially from early research in immune checkpoint therapies.
5. How does this patent landscape compare to other PD-1/PD-L1 patents?
It offers extensive coverage of combination use, distinct from patents focusing on individual antibodies or specific formulations, emphasizing the trend toward combination immunotherapy.
References
[1] Australian Patent AU2010297357. (2010). Antibody combinations for treatment or prevention of cancer.
[2] U.S. Patent No. US9991889B2. (2018). PD-1/PD-L1 antibody combination therapies.
[3] European Patent EP2511114B1. (2017). Immunotherapies targeting PD-1/PD-L1 pathways.
[4] WHO International Patent Classification. (2020). A61K39/00—Medicinal preparations containing antigens or antibodies.
